Neuren Pharmaceuticals Ltd has released a press release.
Presentations and publication for Rett syndrome trials
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Neuren Pharmaceuticals
- Change of Director's Interest Notice
- Notice under section 708A(5)(e) of the Corporations Act
- Results of Meeting
- Neuren Pharmaceuticals reports 2017 half-year results
- Notice of special meeting of shareholders
Later from Neuren Pharmaceuticals
- Neuren FDA meeting confirms Phase 3 plan for Rett syndrome
- Consolidation/Split - NEU
- Neuren announces new US patent to be granted for NNZ-2591
- Preliminary Final Report
- S&P DJ Indices Announces March Quarterly Rebalance
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals